Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 11 of 2158 for:    doxorubicin

Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02237690
Recruitment Status : Completed
First Posted : September 11, 2014
Last Update Posted : June 5, 2017
Sponsor:
Information provided by (Responsible Party):
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Brief Summary:

This is a multi-center, single-dose, open-label, randomized, balanced, two-treatment, two-cycle, two-sequence crossover study to assess bioequivalence of test (T) and reference (R) formulations of doxorubicin hydrochloride liposome injection in female patients with ovarian cancer.

Each patient will be randomized to one of two treatment sequences (RT or TR) according to a randomization scheme prepared prior to the start of the trial.There will be at least 4-week apart between each single-dose administration. Serial blood samples for determination of free doxorubicin and liposomal encapsulated doxorubicin plasma concentrations for PK analysis will be obtained in each cycle.

The 90% confidence intervals on the GMR(geometric mean ratio) of test to reference products of free and liposome encapsulated doxorubicin for PK must be within 80-125% to demonstrate bioequivalence.


Condition or disease Intervention/treatment Phase
Ovarian Cancer Drug: Doxorubicin hydrochloride liposome Phase 1

Detailed Description:

This study has an adaptive 2-stage design. Bioequivalence based on encapsulated doxorubicin will be tested at the end of Stage 1 . An interim analysis of free doxorubicin will be performed at the end of Stage 1 . If needed, the study may continue into Stage 2 with additional number of ovarian cancer patients determined based on the interim analysis; and a final evaluation of bioequivalence for free doxorubicin will be performed at the end of Stage 2. Each patient will be randomized to one of two treatment sequences (RT or TR) according to a randomization scheme prepared prior to the start of the trial. Serial blood samples for determination of free doxorubicin and liposomal encapsulated doxorubicin plasma concentrations for PK analysis will be obtained in each cycle.

The 90% confidence intervals on the GMR(geometric mean ratio) of test to reference products of free and liposome encapsulated doxorubicin for PK must be within 80-125% to demonstrate bioequivalence.

Safety data will be summarized and listed. Adverse events will be coded and classified by system organ class and preferred term using Common Terminology Criteria for Adverse Events. A summary of all drug-related adverse events will also be generated. Clinical laboratory data will be summarized descriptively and listed by treatment group. The change from pre dose to the end of the study will also be summarized. Prior and concomitant medications will be coded with the World Health Organization Drug Dictionary and listed. Vital signs and electrocardiogram data will be summarized and listed by dose group and visit.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open Label, Single-Dose, Two-Cycle Crossover Study to Assess Bioequivalence of Test and Reference Formulations of Doxorubicin Hydrochloride Liposome Injection in Female Patients With Ovarian Cancer
Actual Study Start Date : September 2014
Actual Primary Completion Date : August 2015
Actual Study Completion Date : August 2016


Arm Intervention/treatment
Experimental: doxorubicin hydrochloride liposome(Libaoduo)
Use the test drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang ),then use the reference drug(doxorubicin hydrochloride liposome,from Sunpharma) after at least 4-weeks.
Drug: Doxorubicin hydrochloride liposome
50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.

Active Comparator: doxorubicin hydrochloride liposome
Use the reference drug(doxorubicin hydrochloride liposome,from Sunpharma),then use the test drug drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang) after at least 4-weeks.
Drug: Doxorubicin hydrochloride liposome
50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.




Primary Outcome Measures :
  1. pharmacokinetic(PK) parameter:the maximum plasma doxorubicin concentrations(Cmax) [ Time Frame: 2 cycles ]
    The study endpoint will use the PK parameter(Cmax) for free doxorubicin and liposome encapsulated doxorubicin

  2. PK parameter:the areas under the plasma concentration versus time curve calculated from 0 to the last measurable observation(AUC0-t) [ Time Frame: 2 cycles ]
    The study endpoint will use the PK parameter(AUC0-t) for free doxorubicin and liposome encapsulated doxorubicin(AUC0-t)

  3. PK parameter:the areas under the plasma concentration versus time curve extrapolated from 0 to infinity(AUC0-inf) [ Time Frame: 2 cycles ]
    The study endpoint will use the PK parameter(AUC0-inf) for free doxorubicin and liposome encapsulated doxorubicin


Secondary Outcome Measures :
  1. incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: 2 cycles ]
  2. study discontinuation information [ Time Frame: 2 cycles ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Able to give written informed consent for participation in the trial;
  • Females age 18 to 75 years, inclusive;
  • Histologically or cytologically proven ovarian cancer, which has progressed or recurred by CT/MRI confirmation after platinum-based chemotherapy;
  • ECOG (Eastern Cooperative Oncology Group) Performance Status 0 - 2;
  • Patient is expected to be able to receive both doses of Doxorubicin Hydrochloride Liposome Injection and participate in the trial for at least 56 days.
  • Urine pregnancy test before dosing of both cycle1 and cycle 2 must be negative (not including postmenopausal or surgically sterile women); Agree to use an approved method of birth control (condom with spermicide, diaphragm or cervical cap with spermicide, or intrauterine device); or patients of non-childbearing potential who are either surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or >1 year postmenopausal with follicle-stimulating hormone in the postmenopausal range;

    • 30days or 5 half-lives (whichever is longer) have elapsed from the completion of previous cancer therapy, and patients must have recovered to < Grade 2 or be at new stable baseline from any related toxicities;
  • Adequate renal, hepatic and bone marrow function without blood product or hematopoietic growth factor support:
  • Able to comply with study requirements in the opinion of the Principal Investigator

Exclusion Criteria:

  • Significant allergy, hypersensitivity or idiosyncratic reactions to doxorubicin and/or any related compounds;
  • History or presence of cardiac disease rated New York State Heart Association Classification class 2 or greater;
  • Uncontrolled cardiac arrhythmia or other findings on screening electrocardiogram (ECG) which could, in the judgment of the Principal Investigator, put the patient at undue risk for participation in the trial;
  • LVEF(left ventricular ejection fraction) below 50% or below institutional normal at screening;
  • Prior radiation therapy to mediastinum;
  • Concomitant use of other cytotoxic or cytostatic drugs or of radiotherapy;
  • Active, uncontrolled infection, including opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, or P. carinii;
  • Use of prescription or non-prescription herbal and dietary supplements, within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02237690


Locations
Layout table for location information
China, Beijing
Cancer Institute& Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing, China, 100021
China, Guangdong
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
China, Shandong
QiLu Hospital of Shandong University
Jinan, Shandong, China, 250012
Sponsors and Collaborators
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Wu li ngying, Ph.D Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Principal Investigator: Kong be ihua, Ph.D Shandong University Qilu Hospital
Principal Investigator: Liu ji hong, Ph.D Sun Yat-sen University

Layout table for additonal information
Responsible Party: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT02237690     History of Changes
Other Study ID Numbers: Libaoduo-BE-002
First Posted: September 11, 2014    Key Record Dates
Last Update Posted: June 5, 2017
Last Verified: June 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Doxorubicin
Liposomal doxorubicin
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action